Review Article
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value
Table 3
KRAS and sensitivity to anti-EGFR agents in phase III trial.
| Trial | Anti-EGFR agent | Total number of patients | Patients tested for KRAS | KRAS mutant (%) | Survival in KRAS mutant (HR) |
| TRIBUTE [46] | Gefitinib | 1079 | 264 | 55 (21) | 2.1* | BR. 21 [47] | Erlotinib | 731 | 206 | 30 (15) | 1.67 | SATURN [48] | Erlotinib | 889 | 493 | 90 (18) | 0.79 | ATLAS [15] | Erlotinib | 768 | NR | NR | 0.92 | INTEREST [49] | Gefitinib | 1466 | 275 | 49 (18) | 0.91 | FLEX [57] | Cetuximab | 1125 | 379 | 72 (19) | 1.0 | BMS099 [56] | Cetuximab | 676 | 202 | 35 (17) | 0.95 |
|
|
HR: hazard ratio; NR: not reported. *Statistically significant.
|